Parker-Hannifin Corporation has reported record results for the first quarter of fiscal 2027, which ended on September 30, 2026. The company announced significant growth in sales and earnings, prompting an increase in its full-year guidance. This development is crucial as it highlights Parker-Hannifin's strong performance in a competitive market.
Parker-Hannifin Corp, traded on the New York Stock Exchange under the ticker PH, operates in the Miscellaneous Fabricated Metal Products industry (SIC 3490). The company is based in Cleveland, Ohio, and is recognized as a leader in motion and control technologies. Recent filings indicate a consistent upward trend in financial performance, with the latest 8-K filed on November 5, 2026, detailing the company's operational results.
The filing reveals that for the first quarter, Parker-Hannifin achieved sales of $6.0 billion, marking an 18% increase compared to the same period last year. Organic sales grew by 11.5%, while acquisitions contributed an additional 7%. Net income rose to $0.9 billion, a 9% increase, with adjusted net income showing a more significant increase of 23% to $1.1 billion. Earnings per share (EPS) also saw a notable rise, increasing 10% to $6.92, and adjusted EPS surged 23% to a record $8.90. The segment operating margin improved to 24.4%, reflecting strong demand across all market verticals.
This impressive performance may affect various stakeholders, including investors, employees, and competitors. The increase in sales and profitability positions Parker-Hannifin well against other companies in the Miscellaneous Fabricated Metal Products sector. The successful execution of the company's growth strategies and the recent acquisition of Filtration Group Corporation are likely to enhance its market presence and operational capabilities.
Looking ahead, Parker-Hannifin has raised its full-year guidance for fiscal 2027, anticipating organic sales growth, improved adjusted segment operating margin, and higher adjusted EPS. The company expects reported sales growth of 16% to 19% and organic sales growth of 7.5% to 10.5%. The filing does not specify the next steps, but the positive outlook suggests continued strategic initiatives to capitalize on current market conditions.
Read Next
Korsana Biosciences Reports Third Quarter Financial Results
SCYNEXIS INC reports third-quarter results for 2026
Palvella Therapeutics reports Q3 2026 results, updates pipeline
BlackRock TCP Capital Corp. Reports Q3 Financial Results
Portillo's reports Q3 results, shows revenue growth
Globalstar reports Q3 results, highlights operational metrics




